Fluoxetine cyp3a4 inhibitor

If a strong CYP3A4 inhibitor and strong CYP2D6 inhibitor are coadministered or a known CYP2D6 poor metabolizer is receiving a concomitant strong CYP3A4 inhibitor, the ABILIFY dose should be reduced to one-quarter (25%) of the usual dose, . Strong CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, fluoxetine) inhibitors will increase (2.6 7.1) (2.6 12.3)

Fluoxetine and norfluoxetine are inhibitors of CYP2D6 mediated reactions and demonstrated inhibitory potency toward CYP2C19, CYP2C9, and CYP3A4

Strong CYP3A4. Inhibitors (e.g, itraconazole, clarithromycin) or strong CYP2D6 inhibitors (e.g, quinidine, fluoxetine, paroxetine). The concomitant use of

Aripiprazole may interact with strong CYP3A4 inhibitors (such as itraconazole, clarithromycin) or CYP2D6 inhibitors (such as fluoxetine, paroxetine).

If intolerable adverse effects occur when coadministered with moderate CYP3A4 inhibitors, reduce daily dose to 20 mg. fluoxetine. fluoxetine, vilazodone.

The selective serotonin reuptake inhibitors sertraline (weak CYP3A4 inducer) and fluoxetine (CYP2D6 inhibitor), and the anti-epileptic drug felbamate

by TOM LYNCH 2024 Cited by 1425Ritonavir (Norvir), a protease inhibitor and potent CYP3A4 inhibitor Fluoxetine (Prozac), paroxetine (Paxil), CYP2D6 inhibitor

If a strong CYP3A4 inhibitor and strong CYP2D6 inhibitor are coadministered or a known CYP2D6 poor metabolizer is receiving a concomitant strong CYP3A4 inhibitor, the ABILIFY dose should be reduced to one-quarter (25%) of the usual dose, . Strong CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, fluoxetine) inhibitors will increase (2.6 7.1) (2.6 12.3)

Other strong inhibitors of CYP2D6, such as fluoxetine and paroxetine, may be Ketoconazole and other CYP3A4 inhibitors. In a clinical trial in healthy subjects